161 related articles for article (PubMed ID: 17919914)
21. Design, synthesis and evaluation of 7-azaindazolyl-indolyl-maleimides as glycogen synthase kinase-3β (GSK-3β) inhibitors.
Ye Q; Shen Y; Zhou Y; Lv D; Gao J; Li J; Hu Y
Eur J Med Chem; 2013 Oct; 68():361-71. PubMed ID: 23994329
[TBL] [Abstract][Full Text] [Related]
22. 1,2,4-Thiadiazole acyclic nucleoside phosphonates as inhibitors of cysteine dependent enzymes cathepsin K and GSK-3β.
Pomeislová A; Otmar M; Rubešová P; Benýšek J; Matoušová M; Mertlíková-Kaiserová H; Pohl R; Poštová Slavětínská L; Pomeisl K; Krečmerová M
Bioorg Med Chem; 2021 Feb; 32():115998. PubMed ID: 33440320
[TBL] [Abstract][Full Text] [Related]
23. Structural basis for the GSK-3beta binding affinity and selectivity against CDK-2 of 1-(4-aminofurazan-3yl)-5-dialkylaminomethyl-1H-[1,2,3] triazole-4-carboxylic acid derivatives.
Pande V; Ramos MJ
Bioorg Med Chem Lett; 2005 Dec; 15(23):5129-35. PubMed ID: 16213715
[TBL] [Abstract][Full Text] [Related]
24. Glycogen synthase kinase-3beta inhibition attenuates asthma in mice.
Bao Z; Lim S; Liao W; Lin Y; Thiemermann C; Leung BP; Wong WS
Am J Respir Crit Care Med; 2007 Sep; 176(5):431-8. PubMed ID: 17556716
[TBL] [Abstract][Full Text] [Related]
25. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
26. The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.
Gao Y; Ye DY; Zhou WC; Chu Y
Eur J Med Chem; 2017 Jul; 135():370-381. PubMed ID: 28460311
[TBL] [Abstract][Full Text] [Related]
27. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
Darshit BS; Balaji B; Rani P; Ramanathan M
J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
[TBL] [Abstract][Full Text] [Related]
28. GSK-3beta inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes.
Evenson AR; Fareed MU; Menconi MJ; Mitchell JC; Hasselgren PO
Int J Biochem Cell Biol; 2005 Oct; 37(10):2226-38. PubMed ID: 16051512
[TBL] [Abstract][Full Text] [Related]
29. Glycogen synthase kinase-3β inhibition of 6-(methylsulfinyl)hexyl isothiocyanate derived from wasabi (Wasabia japonica Matsum).
Yoshida J; Nomura S; Nishizawa N; Ito Y; Kimura K
Biosci Biotechnol Biochem; 2011; 75(1):136-9. PubMed ID: 21228474
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and biological evaluation of 5-benzylidene-2-iminothiazolidin-4-ones as selective GSK-3β inhibitors.
Arfeen M; Bhagat S; Patel R; Prasad S; Roy I; Chakraborti AK; Bharatam PV
Eur J Med Chem; 2016 Oct; 121():727-736. PubMed ID: 27423119
[TBL] [Abstract][Full Text] [Related]
31. Inhibiting glycogen synthase kinase 3beta in sepsis.
Dugo L; Collin M; Allen DA; Patel NS; Bauer I; Mervaala E; Louhelainen M; Foster SJ; Yaqoob MM; Thiemermann C
Novartis Found Symp; 2007; 280():128-42; discussion 142-6, 160-4. PubMed ID: 17380792
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of glycogen synthase kinase-3beta attenuates the development of carrageenan-induced lung injury in mice.
Cuzzocrea S; Crisafulli C; Mazzon E; Esposito E; Muià C; Abdelrahman M; Di Paola R; Thiemermann C
Br J Pharmacol; 2006 Nov; 149(6):687-702. PubMed ID: 17016509
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors.
La Pietra V; La Regina G; Coluccia A; Famiglini V; Pelliccia S; Plotkin B; Eldar-Finkelman H; Brancale A; Ballatore C; Crowe A; Brunden KR; Marinelli L; Novellino E; Silvestri R
J Med Chem; 2013 Dec; 56(24):10066-78. PubMed ID: 24295046
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
Shin D; Lee SC; Heo YS; Lee WY; Cho YS; Kim YE; Hyun YL; Cho JM; Lee YS; Ro S
Bioorg Med Chem Lett; 2007 Oct; 17(20):5686-9. PubMed ID: 17764934
[TBL] [Abstract][Full Text] [Related]
35. Structure based de novo design of novel glycogen synthase kinase 3 inhibitors.
Dessalew N; Bharatam PV
Bioorg Med Chem; 2007 Jun; 15(11):3728-36. PubMed ID: 17399989
[TBL] [Abstract][Full Text] [Related]
36. Synthesis of Coumarin Derivatives as Versatile Scaffolds for GSK-3β Enzyme Inhibition.
Francisco CS; Javarini CL; de S Barcelos I; Morais PAB; de Paula H; de S Borges W; Neto ÁC; Lacerda V
Curr Top Med Chem; 2020; 20(2):153-160. PubMed ID: 31648640
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of glycogen synthase kinase-3β prevents NSAID-induced acute kidney injury.
Bao H; Ge Y; Zhuang S; Dworkin LD; Liu Z; Gong R
Kidney Int; 2012 Apr; 81(7):662-73. PubMed ID: 22258319
[TBL] [Abstract][Full Text] [Related]
38. Involvement of glycogen synthase kinase-3beta in palmitate-induced human umbilical vein endothelial cell apoptosis.
Choi SE; Kang Y; Jang HJ; Shin HC; Kim HE; Kim HS; Kim HJ; Kim DJ; Lee KW
J Vasc Res; 2007; 44(5):365-74. PubMed ID: 17483602
[TBL] [Abstract][Full Text] [Related]
39. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.
Lo Monte F; Kramer T; Gu J; Anumala UR; Marinelli L; La Pietra V; Novellino E; Franco B; Demedts D; Van Leuven F; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B
J Med Chem; 2012 May; 55(9):4407-24. PubMed ID: 22533818
[TBL] [Abstract][Full Text] [Related]
40. Discovery of potent and bioavailable GSK-3beta inhibitors.
Gong L; Hirschfeld D; Tan YC; Heather Hogg J; Peltz G; Avnur Z; Dunten P
Bioorg Med Chem Lett; 2010 Mar; 20(5):1693-6. PubMed ID: 20138512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
